PubRank

Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer

Clinical Trial ID NCT00788333

PubWeight™ 17.14‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00788333

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol 2013 1.59
2 Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol 2012 1.26
3 Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 2012 1.23
4 Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer 2012 1.12
5 Targeting insulin and insulin-like growth factor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2012 1.08
6 The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer 2015 1.05
7 Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol 2012 1.05
8 Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent Pat Anticancer Drug Discov 2012 1.00
9 The insulin receptor: a new target for cancer therapy. Front Endocrinol (Lausanne) 2011 0.99
10 Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta 2014 0.96
11 Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer. Int J Breast Cancer 2012 0.92
12 Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad? Invest New Drugs 2012 0.92
13 Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. Oncologist 2014 0.89
14 Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One 2012 0.88
15 Current Approaches and Emerging Directions in HER2-resistant Breast Cancer. Breast Cancer (Auckl) 2014 0.87
16 Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives. Oncol Rev 2013 0.79
17 Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. Ther Adv Med Oncol 2015 0.79
Next 100